Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SND002 Cell Injection in Advanced Malignant Solid Tumors
NCT07903857Phase 1Not yet recruiting
- Sponsor
- Guizhou Sinorda Pharmaceutical
- Start
- Dec 2026
- Primary completion
- Aug 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SND002 in solid tumor, sponsored by Guizhou Sinorda Pharmaceutical. Primary endpoints: Number of participants with treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities at 28 days, Recommended cell-dose range for further study and 2 more. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
SND002
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07903857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07903857.